Ethacrynic Acid NDC 72162-2257

NDC codes

FDA NDC Directory

Product NDC (as listed)72162-2257Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72162-2257Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72162-2257-1	72162225701	100 TABLET in 1 BOTTLE (72162-2257-1)Marketed from Aug 27, 2019

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ethacrynic Acid
Generic name (nonproprietary): ethacrynic acid
Active ingredients: Ethacrynic acid — 25 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211232
Marketing start: Aug 27, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Increased Diuresis at Loop of Henle (Physiologic effect)
Identifiers: Product ID 72162-2257_6ee91f7d-ffd8-4045-819a-d0e9764803dbSPL ID 6ee91f7d-ffd8-4045-819a-d0e9764803dbSPL set ID fd1b7fb4-fe56-4f2d-860d-bbcea16adfeaRxCUI 1251903UNII M5DP350VZV
Pharmacologic class: Loop Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472162225701 followed by a unit qualifier and the quantity

Package 72162-2257-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 4, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Ethacrynic Acid Tablets, USP are indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211232

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211232
Product	Strength	Form · route	Labeler	Product NDC
Ethacrynic Acid	Ethacrynic acid 25 mg/1	TabletOral	St. Mary's Medical Park Pharmacy	60760-773
Ethacrynic Acid	Ethacrynic acid 25 mg/1	TabletOral	ScieGen Pharmaceuticals Inc	50228-334